What is he best known for?
The fields of study he is best known for:
Hans J. Hansen spends much of his time researching Antibody, Antigen, Monoclonal antibody, Molecular biology and Immunology.
His study in Antibody is interdisciplinary in nature, drawing from both Pathology, Carcinoembryonic antigen and Virology.
His research investigates the connection between Antigen and topics such as Immunotherapy that intersect with problems in Peptide.
His study on Monoclonal antibody also encompasses disciplines like
- Lymphoma together with Chemotherapy,
- Pharmacology which connect with Immunoconjugate, Biodistribution and Biochemistry.
His biological study spans a wide range of topics, including Immunoglobulin light chain, Constant region, Glycosylation and Raji cell.
Hans J. Hansen works mostly in the field of Immunology, limiting it down to concerns involving Cancer research and, occasionally, Pretargeting.
His most cited work include:
- Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells (359 citations)
- Anti-cd20 antibodies and fusion proteins thereof and methods of use (245 citations)
- Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma (234 citations)
What are the main themes of his work throughout his whole career to date?
Hans J. Hansen mostly deals with Antibody, Molecular biology, Monoclonal antibody, Antigen and Immunology.
The Antibody study combines topics in areas such as Carcinoembryonic antigen, Cancer research, Virology, Biochemistry and Fusion protein.
Hans J. Hansen works mostly in the field of Carcinoembryonic antigen, limiting it down to topics relating to Pathology and, in certain cases, Cancer, as a part of the same area of interest.
His Molecular biology research is multidisciplinary, incorporating elements of Specific antibody, Glycosylation, Immunoglobulin light chain, Primary and secondary antibodies and Epitope.
As part of the same scientific family, Hans J. Hansen usually focuses on Monoclonal antibody, concentrating on Pharmacology and intersecting with Toxicity.
He studies Hapten which is a part of Antigen.
He most often published in these fields:
- Antibody (50.49%)
- Molecular biology (26.71%)
- Monoclonal antibody (25.08%)
What were the highlights of his more recent work (between 2005-2019)?
- Antibody (50.49%)
- Immunology (20.20%)
- Monoclonal antibody (25.08%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Antibody, Immunology, Monoclonal antibody, Antigen and Fusion protein.
His Antibody study incorporates themes from Molecular biology, Cancer research and Moiety.
Hans J. Hansen combines subjects such as Amino acid, Cancer and Primary and secondary antibodies with his study of Molecular biology.
His work on Immune system, Rituximab, CD74 and Innate immune system as part of general Immunology research is often related to Proinflammatory cytokine, thus linking different fields of science.
Hans J. Hansen has researched Monoclonal antibody in several fields, including Emulsion and Lung.
His Fusion protein study also includes
- Virology most often made with reference to Human b cell,
- Carcinoma most often made with reference to Alpha-fetoprotein.
Between 2005 and 2019, his most popular works were:
- CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms (172 citations)
- Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. (170 citations)
- Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. (156 citations)
In his most recent research, the most cited papers focused on:
His primary areas of study are Antibody, Monoclonal antibody, Immunology, Antibody-dependent cell-mediated cytotoxicity and Rituximab.
His Biochemistry research extends to the thematically linked field of Antibody.
His Monoclonal antibody research is multidisciplinary, incorporating perspectives in Emulsion, Sepharose, Drug carrier and Antigen.
While the research belongs to areas of Immunology, Hans J. Hansen spends his time largely on the problem of Cancer research, intersecting his research to questions surrounding Colorectal cancer, Pancreatic cancer, Labetuzumab, Transplantation and Pathology.
In his work, B-cell lymphoma, Molecular biology and Monoclonal is strongly intertwined with CD22, which is a subfield of Antibody-dependent cell-mediated cytotoxicity.
In his research on the topic of Rituximab, Epratuzumab, Veltuzumab, Immunoglobulin G, Fragment crystallizable region and Effector is strongly related with Humanized antibody.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
